These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 11175818)

  • 1. Overstimulation of the alpha1B-adrenergic receptor causes a "seizure plus" syndrome.
    Seppi K; Puschban Z; Stefanova N; Scherfler C; Mueller J; Poewe W; Wenning GK
    Nat Med; 2001 Feb; 7(2):132. PubMed ID: 11175818
    [No Abstract]   [Full Text] [Related]  

  • 2. Mice expressing the alpha(1B)-adrenergic receptor induces a synucleinopathy with excessive tyrosine nitration but decreased phosphorylation.
    Papay R; Zuscik MJ; Ross SA; Yun J; McCune DF; Gonzalez-Cabrera P; Gaivin R; Drazba J; Perez DM
    J Neurochem; 2002 Nov; 83(3):623-34. PubMed ID: 12390524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of the alpha1B-adrenergic receptor causes apoptotic neurodegeneration: multiple system atrophy.
    Zuscik MJ; Sands S; Ross SA; Waugh DJ; Gaivin RJ; Morilak D; Perez DM
    Nat Med; 2000 Dec; 6(12):1388-94. PubMed ID: 11100125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of D3 receptors in the zitter mutant rat is not reversed by L-dopa treatment.
    Joyce JN; Der TC; Renish L; Osredkar T; Hagner D; Reploge M; Sakakibara S; Ueda S
    Exp Neurol; 2004 May; 187(1):178-89. PubMed ID: 15081599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease.
    Auluck PK; Chan HY; Trojanowski JQ; Lee VM; Bonini NM
    Science; 2002 Feb; 295(5556):865-8. PubMed ID: 11823645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 5-HT2A and alpha1b-adrenergic receptors entirely mediate dopamine release, locomotor response and behavioural sensitization to opiates and psychostimulants.
    Auclair A; Drouin C; Cotecchia S; Glowinski J; Tassin JP
    Eur J Neurosci; 2004 Dec; 20(11):3073-84. PubMed ID: 15579162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experimental models of Parkinson's disease.
    Beal MF
    Nat Rev Neurosci; 2001 May; 2(5):325-34. PubMed ID: 11331916
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for neurofilament inclusion disease using alpha-internexin immunohistochemistry.
    Uchikado H; Shaw G; Wang DS; Dickson DW
    Neurology; 2005 May; 64(9):1658-9. PubMed ID: 15883343
    [No Abstract]   [Full Text] [Related]  

  • 9. Neuroprotective effect of L-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson's disease: a direct comparison study.
    Shin JY; Park HJ; Ahn YH; Lee PH
    J Neurochem; 2009 Nov; 111(4):1042-50. PubMed ID: 19765187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys.
    Julien C; Berthiaume L; Hadj-Tahar A; Rajput AH; Bédard PJ; Di Paolo T; Julien P; Calon F
    Neurochem Int; 2006 Apr; 48(5):404-14. PubMed ID: 16442670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spatial patterns of alpha-synuclein positive glial cytoplasmic inclusions in multiple system atrophy.
    Armstrong RA; Lantos PL; Cairns NJ
    Mov Disord; 2004 Jan; 19(1):109-12. PubMed ID: 14743371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atypical parkinsonism combining alpha-synuclein inclusions and polyglucosan body disease.
    Krim E; Vital A; Macia F; Yekhlef F; Tison F
    Mov Disord; 2005 Feb; 20(2):200-4. PubMed ID: 15382212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuronal inclusions in degenerative disorders Do they represent static features or a key to understand the dynamics of the disease?
    Fornai F; Soldani P; Lazzeri G; di Poggio AB; Biagioni F; Fulceri F; Batini S; Ruggieri S; Paparelli A
    Brain Res Bull; 2005 Apr; 65(4):275-90. PubMed ID: 15811592
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phosphorylated alpha-synuclein in normal mouse brain.
    Hirai Y; Fujita SC; Iwatsubo T; Hasegawa M
    FEBS Lett; 2004 Aug; 572(1-3):227-32. PubMed ID: 15304353
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene expression profile of neurodegeneration induced by alpha1B-adrenergic receptor overactivity: NMDA/GABAA dysregulation and apoptosis.
    Yun J; Gaivin RJ; McCune DF; Boongird A; Papay RS; Ying Z; Gonzalez-Cabrera PJ; Najm I; Perez DM
    Brain; 2003 Dec; 126(Pt 12):2667-81. PubMed ID: 12937073
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alpha-synuclein and neurodegenerative diseases.
    Goedert M
    Nat Rev Neurosci; 2001 Jul; 2(7):492-501. PubMed ID: 11433374
    [No Abstract]   [Full Text] [Related]  

  • 17. Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning.
    Guigoni C; Dovero S; Aubert I; Li Q; Bioulac BH; Bloch B; Gurevich EV; Gross CE; Bezard E
    Eur J Neurosci; 2005 Jul; 22(1):283-7. PubMed ID: 16029219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levodopa but not ropinirole induces an internalization of D1 dopamine receptors in parkinsonian rats.
    Muriel MP; Orieux G; Hirsch EC
    Mov Disord; 2002 Nov; 17(6):1174-9. PubMed ID: 12465054
    [TBL] [Abstract][Full Text] [Related]  

  • 19. L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.
    Huot P; Lévesque M; Morissette M; Calon F; Dridi M; Di Paolo T; Parent A
    J Chem Neuroanat; 2008 Jan; 35(1):77-84. PubMed ID: 17706922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurodegenerative disorders with diffuse cortical Lewy bodies.
    Fleisher AS; Olichney JM
    Adv Neurol; 2005; 96():148-65. PubMed ID: 16383218
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.